skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function

Journal Article · · Clin. Pharmacol. Ther.; (United States)
DOI:https://doi.org/10.1038/clpt.1986.46· OSTI ID:5677130

The pharmacokinetics of 14C-labeled glyburide were studied in 13 men with varying degrees of renal impairment. Patients received a single, 5 mg oral dose of glyburide as a solution (10 microCi/ml/mg) after a high-carbohydrate breakfast. Serial plasma and breath samples were collected for 48 hours and urine and feces were collected for 5 to 7 days. Patients with normal to moderately impaired renal function (creatinine clearance (CLCR) of 29 to 131 ml/min/1.7 m2) had glyburide plasma t1/2 values of 2.0 to 5.0 hours, with no relationship between CLCR and glyburide clearance. One subject with severe renal impairment (CLCR = 5 ml/min/1.7 m2) had decreased glyburide clearance that resulted in a t1/2 of 11 hours. The elimination of metabolites was more dependent on renal status but was only significantly affected in the patient with severe renal impairment.

Research Organization:
Ferris State College, Big Rapids, MI
OSTI ID:
5677130
Journal Information:
Clin. Pharmacol. Ther.; (United States), Vol. 3
Country of Publication:
United States
Language:
English